Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEXUS study of ANXV in diabetic retinopathy or recent retinal vein occlusion
2026-525349-65-00Phase 2Authorised
- Sponsor
- Annexin Pharmaceuticals AB
- Start
- May 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, open-label trial of annexin a5 in diabetic retinopathy (DR) and Vein occlusion (RVO) (2 cohorts), sponsored by Annexin Pharmaceuticals AB. Primary endpoints: Treatment-emergent adverse events and serious adverse events and Anti-drug antibodies to ANXV. Planned start May 2026; status: authorised.
02
Drugs
annexin a5
03
Conditions
diabetic retinopathy (DR)Vein occlusion (RVO)
Beyond the preview
Go deeper on 2026-525349-65-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525349-65-00.